ERBB2 and neoplasm: However PET/CT studies are not widely available for clinical practice, whereas Ki67 and tumor response at 11 days are practical for wider implementation in the neoadjuvant setting to predict response on dual anti-HER2 therapy potentially reducing toxicity.